By Sabela Ojea

 

AstraZeneca PLC said Friday that the combination of its Imfinzi drug and tremelimumab with chemotherapy showed an overall survival benefit in its metastatic non-small cell lung cancer Phase 3 Poseidon trial.

The pharmaceutical company added that the use of Imfinzi with chemotherapy didn't achieve a trend in overall survival.

"We've seen encouraging uptake of novel combinations in this setting and believe this new approach will add a further option for patients with high unmet medical need," said Dave Fredrickson, executive vice president of Astrazeneca's oncology business unit.

 

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

 

(END) Dow Jones Newswires

May 07, 2021 02:33 ET (06:33 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.